These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 22859719

  • 1. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB.
    Clin Cancer Res; 2012 Oct 01; 18(19):5304-13. PubMed ID: 22859719
    [Abstract] [Full Text] [Related]

  • 2. Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.
    Hall B, Nakashima H, Sun ZJ, Sato Y, Bian Y, Husain SR, Puri RK, Kulkarni AB.
    J Transl Med; 2013 Feb 19; 11():45. PubMed ID: 23421960
    [Abstract] [Full Text] [Related]

  • 3. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.
    Clin Cancer Res; 2013 Jul 15; 19(14):3808-19. PubMed ID: 23640975
    [Abstract] [Full Text] [Related]

  • 4. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation.
    Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, Waes CV, Kulkarni AB.
    Oncogene; 2012 Jul 12; 31(28):3322-32. PubMed ID: 22037217
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.
    Sun ZJ, Zhang L, Zhang W, Hall B, Bian Y, Kulkarni AB.
    PLoS One; 2013 Jul 12; 8(10):e74888. PubMed ID: 24124460
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT, Mao L, Wu L, Deng WW, Bu LL, Liu JF, Chen L, Yang LL, Wu H, Zhang WF, Sun ZJ.
    Cell Mol Life Sci; 2018 Nov 12; 75(22):4223-4234. PubMed ID: 29955905
    [Abstract] [Full Text] [Related]

  • 7. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L, Zhang W, Wang YF, Liu B, Zhang WF, Zhao YF, Kulkarni AB, Sun ZJ.
    Cell Death Dis; 2015 May 28; 6(5):e1771. PubMed ID: 26018732
    [Abstract] [Full Text] [Related]

  • 8. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
    Ma SR, Wang WM, Huang CF, Zhang WF, Sun ZJ.
    Oncotarget; 2015 Apr 20; 6(11):8807-21. PubMed ID: 25871396
    [Abstract] [Full Text] [Related]

  • 9. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 10. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway.
    Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P, Chen W, Flanders KC, Gutkind JS, Wakefield LM, Kulkarni AB.
    Cancer Res; 2009 Jul 15; 69(14):5918-26. PubMed ID: 19584284
    [Abstract] [Full Text] [Related]

  • 11. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
    Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS.
    Cancer Res; 2008 Feb 15; 68(4):1144-53. PubMed ID: 18281490
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS.
    Clin Cancer Res; 2019 Feb 15; 25(4):1156-1164. PubMed ID: 30420444
    [Abstract] [Full Text] [Related]

  • 13. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 14. NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma.
    Huang CF, Chen L, Li YC, Wu L, Yu GT, Zhang WF, Sun ZJ.
    J Exp Clin Cancer Res; 2017 Sep 02; 36(1):116. PubMed ID: 28865486
    [Abstract] [Full Text] [Related]

  • 15. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model.
    Raimondi AR, Molinolo A, Gutkind JS.
    Cancer Res; 2009 May 15; 69(10):4159-66. PubMed ID: 19435901
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY.
    Clin Cancer Res; 2008 Mar 01; 14(5):1581-9. PubMed ID: 18316583
    [Abstract] [Full Text] [Related]

  • 17. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH.
    Neoplasia; 2013 Jun 01; 15(6):620-30. PubMed ID: 23730210
    [Abstract] [Full Text] [Related]

  • 18. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ, Guerra-Librero A, Fernandez-Gil BI, Florido J, García-López S, Martinez-Ruiz L, Mendivil-Perez M, Soto-Mercado V, Acuña-Castroviejo D, Ortega-Arellano H, Carriel V, Diaz-Casado ME, Reiter RJ, Rusanova I, Nieto A, López LC, Escames G.
    J Pineal Res; 2018 Apr 01; 64(3):. PubMed ID: 29247557
    [Abstract] [Full Text] [Related]

  • 19. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.
    Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS.
    Cancer Prev Res (Phila); 2009 Jan 01; 2(1):27-36. PubMed ID: 19139015
    [Abstract] [Full Text] [Related]

  • 20. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J, Li Q, Ding X, Gao Y.
    Cell Physiol Biochem; 2018 Jan 01; 46(2):676-686. PubMed ID: 29621758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.